Is Egrifta (Tesamorelin) Legal in California?

The FDA Approval Behind Egrifta

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The FDA approved the original Egrifta formulation in November 2010 specifically to reduce excess abdominal fat in HIV-positive adults with lipodystrophy caused by antiretroviral therapy. [1] A reformulated version, Egrifta SV (2 mg/vial), received FDA approval in 2019 and replaced the original on the US market. [2]

What the Approval Covers

The approved indication is narrow: excess visceral abdominal fat in HIV-infected adults receiving antiretroviral treatment. The prescribing information sets the approved dose at 2 mg subcutaneously once daily. [2] Tesamorelin is not approved for general weight loss, anti-aging, or athletic performance.

Why Approval Matters for Legality

An FDA-approved drug may be legally prescribed, dispensed, and administered in every US state, including California, once it clears federal review. [3] California does not need to pass separate legislation to allow a federally approved drug. The California Business and Professions Code section 4040 defines "prescription" consistently with federal definitions, so a valid Rx for Egrifta SV written by a California-licensed prescriber is fully lawful. [4]

Phase III Data Supporting the Indication

The approval rested on two phase III randomized controlled trials. The LIPO-010 trial (N=412) showed tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% versus 5% with placebo at 26 weeks (P<0.001). [5] A second 52-week extension confirmed durability of effect. The FDA Medical Officer's review concluded the benefit-risk profile was favorable specifically in the HIV-lipodystrophy population. [1]

Federal Legal Framework That Governs California Access

California cannot create a separate drug-approval pathway. Federal law, primarily the Food, Drug, and Cosmetic Act (FD&C Act) and the Drug Supply Chain Security Act, controls what pharmacies may dispense and what physicians may prescribe. [3]

Prescription Drug Status

Tesamorelin is a prescription-only drug under 21 CFR 310. It is not scheduled under the Controlled Substances Act, so DEA registration is not required for a prescriber to write for it. [6] Any California physician, nurse practitioner, or physician assistant holding a valid Drug Enforcement Administration registration (required to prescribe any controlled substance) may prescribe Egrifta SV without a separate DEA order form. A standard California prescription pad or electronic prescription is sufficient.

The 503A Compounding Route

Section 503A of the FD&C Act allows a state-licensed pharmacy to compound a drug product for an individual patient when a valid prescription exists and the bulk active pharmaceutical ingredient (API) appears on FDA's approved bulk-substances list. [7] Tesamorelin's status on that list has shifted: the FDA 2023 nominated-substances update did not place tesamorelin on the Category 1 (suitable for use) list for 503A pharmacies. [8]

That means a 503A pharmacy may not compound tesamorelin without a specific clinical need documented in the prescription that demonstrates the compounded version differs meaningfully from available commercial product. Prescribers and patients in California should verify current status directly with FDA before ordering a compounded tesamorelin product from a 503A pharmacy.

The 503B Outsourcing Facility Route

Section 503B of the FD&C Act covers FDA-registered outsourcing facilities, which may compound without individual patient prescriptions and sell to health care facilities. [7] A 503B facility compounding tesamorelin must use a bulk API that meets USP or equivalent quality standards and must operate under current Good Manufacturing Practice (cGMP). California has several FDA-registered 503B facilities. Whether any currently compound tesamorelin depends on FDA's bulk-substances decisions and the facility's own formulary. Patients should ask their prescriber to confirm 503B registration before ordering.

FDA Bulk-Substances List: The Gray Area Explained

The FDA's Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (2016) established that compounders may use a bulk substance only if FDA has evaluated it or it appears on the 503A bulks list. [8] Tesamorelin has been nominated but has not yet received a final Category 1 determination. Until that determination is issued, 503A compounding of tesamorelin occupies a genuine regulatory gray area. FDA's enforcement discretion policy means prosecutions are unlikely for pharmacies following all other 503A requirements, but the legal basis is less firm than it would be for a Category 1 substance. [8]

California-Specific Rules for Prescribers and Pharmacies

California follows federal drug law as a floor, then adds state-level pharmacy and medical-practice requirements on top.

California Medical Practice Act and Off-Label Prescribing

The California Medical Practice Act (Business and Professions Code sections 2050 to 2079) permits off-label prescribing when a physician exercises independent professional judgment and documents a rational clinical basis. [4] A California physician may therefore prescribe tesamorelin off-label (for example, for growth-hormone deficiency not caused by HIV) as long as:

• The physician holds a valid, active California medical license
• A genuine prescriber-patient relationship exists, as required by the Medical Board of California
• The clinical rationale is documented in the medical record
• The patient provides informed consent that addresses off-label status

California State Board of Pharmacy Requirements

The California State Board of Pharmacy requires any pharmacy dispensing compounded products to a California patient to hold either a California nonresident pharmacy permit (if located outside the state) or a standard California pharmacy license. [9] A 503A compounder in Texas, for example, must hold a California nonresident permit to mail tesamorelin to a California address. Patients should ask their pharmacy for their California permit number before accepting a shipment.

Telehealth Prescribing Under California AB 2897

California Assembly Bill 2897 (effective January 2023) explicitly allows prescribers to establish a valid patient relationship and issue prescriptions via synchronous audio-video telehealth without a prior in-person visit for most non-controlled substances. [10] Because tesamorelin is not a controlled substance, a California telehealth physician may legally evaluate a patient, diagnose HIV-related lipodystrophy or another clinical indication, and send an Egrifta SV or compounded tesamorelin prescription to a licensed pharmacy without the patient ever setting foot in a clinic.

The HealthRX clinical team uses a four-step eligibility screen before tesamorelin is prescribed via telehealth in California:

1. Confirm HIV-positive status and current antiretroviral regimen, or document an alternative clinical indication with supporting labs (IGF-1, fasting glucose, HbA1c)
2. Obtain baseline waist circumference and visceral fat estimate (DXA or CT if available; waist-to-hip ratio if not)
3. Screen for contraindications: active malignancy, hypersensitivity to tesamorelin or mannitol, pregnancy
4. Verify that the dispensing pharmacy holds a current California license or nonresident permit

Contraindications and Safety Signals Affecting Prescribing Decisions

No prescribing discussion is complete without safety context. The Egrifta SV prescribing information lists active malignancy and hypersensitivity to tesamorelin or mannitol as absolute contraindications. [2] Tesamorelin raises IGF-1 levels; the LIPO-010 data showed a mean IGF-1 increase of 114 ng/mL from baseline versus 4 ng/mL with placebo. [5] Elevated IGF-1 carries a theoretical cancer-promotion risk that has not been resolved in long-term prospective data.

Glucose Metabolism Effects

Tesamorelin may worsen glucose tolerance. In the LIPO-010 trial, fasting glucose increased by a mean of 3.6 mg/dL in the tesamorelin arm versus 0.3 mg/dL with placebo. [5] The FDA label carries a specific warning about glucose intolerance; prescribers must monitor HbA1c at baseline and at 3-month intervals. [2] Patients with type 2 diabetes or pre-diabetes require closer monitoring and may need antidiabetic medication adjustment.

Fluid Retention

Peripheral edema occurred in 6.3% of tesamorelin-treated patients versus 2.0% of placebo patients in pooled trial data cited in the FDA label. [2] Joint pain and myalgia are also more common with active treatment. These adverse effects are typically mild and reversible on discontinuation.

How to Get a Legal Tesamorelin Prescription in California

A California patient seeking Egrifta SV or compounded tesamorelin has three practical channels.

Channel 1: HIV Specialist or Endocrinologist (In-Person)

An HIV specialist or endocrinologist can evaluate visceral fat burden, order confirmatory imaging, and write a brand-name Egrifta SV prescription covered by insurance when HIV-related lipodystrophy is the documented diagnosis. Medicare Part D and many commercial plans cover Egrifta SV with prior authorization. The manufacturer (Theratechnologies) maintains a patient assistance program for uninsured patients. [11]

Channel 2: Telehealth Hormone Clinic

For patients with off-label clinical indications (such as adult growth-hormone deficiency documented by provocative testing per the Endocrine Society 2011 guidelines), a California-licensed telehealth prescriber may order compounded tesamorelin from a licensed 503B outsourcing facility. [12] The Endocrine Society's 2011 clinical practice guideline for growth hormone deficiency states: "We recommend against GH treatment in patients who have evidence of active malignancy... And suggest that GH therapy be considered for adults with severe GHD." [12] Tesamorelin is not growth hormone, but its GHRH-analogue mechanism produces similar downstream GH secretion, and some clinicians use it when GH replacement itself is not preferred by the patient.

Channel 3: Direct Pay Compounding Pharmacy

A patient with a valid California prescription may order compounded tesamorelin directly from a 503A or 503B pharmacy. Average direct-pay pricing for compounded tesamorelin ranges from roughly $150 to $400 per month depending on dose and vendor, compared to Egrifta SV list prices exceeding $5,000 per month. Given the gray-area status of tesamorelin on the FDA 503A bulks list, patients should request written documentation from the pharmacy confirming its regulatory basis for compounding. [8]

What Is Unambiguously Illegal in California

Several sourcing routes expose California patients to federal felony charges or state misdemeanors.

Importing tesamorelin from an unregistered overseas supplier without FDA authorization violates 21 USC 331 and 21 USC 333 and may constitute importation of a misbranded or unapproved drug. [3] Purchasing tesamorelin labeled "for research use only" from a domestic research-chemical vendor and self-injecting it violates the FD&C Act's prescription-drug requirements because no valid prescription covers research-chemical use. [3] Obtaining a prescription from a prescriber who does not conduct a real clinical evaluation violates California Business and Professions Code section 2242, which prohibits prescribing without a good-faith examination. [4]

The California Department of Consumer Affairs can revoke a physician's medical license for prescribing without a valid clinical basis. Patients who knowingly obtain a prescription through fraud may face prosecution under California Penal Code section 4324 (prescription fraud). [4]

Insurance Coverage and Prior Authorization in California

Brand-name Egrifta SV carries prior-authorization requirements on virtually every California payer. The prescriber must document:

• HIV-positive diagnosis with current antiretroviral regimen
• Evidence of excess visceral fat (imaging preferred; waist circumference acceptable to some plans)
• Absence of uncontrolled diabetes or active malignancy
• Failure or contraindication to lifestyle modification alone

Medi-Cal (California's Medicaid program) covers Egrifta SV under the HIV/AIDS Drug Assistance Program (ADAP) formulary for eligible HIV-positive patients. [13] Compounded tesamorelin is almost never covered by commercial insurance because it is not an FDA-approved finished drug product.

Monitoring Protocol Once Treatment Begins

The Endocrine Society and the FDA label both support structured monitoring. After initiating tesamorelin 2 mg subcutaneously once daily:

• Measure IGF-1 at 6 weeks and every 6 months; if IGF-1 exceeds 2 standard deviations above age- and sex-adjusted mean, reduce dose or discontinue [12]
• Check HbA1c and fasting glucose at baseline, 3 months, and 6 months [2]
• Reassess visceral fat reduction at 26 weeks; if no meaningful response by 26 weeks, the FDA label recommends considering discontinuation [2]
• Screen for injection-site reactions at each visit; lipoatrophy at the injection site has been reported

A 2012 follow-up analysis of the LIPO-010 extension showed that visceral fat returned toward baseline within 6 months of stopping tesamorelin, confirming that treatment effects are not permanent and ongoing therapy is required to maintain benefit. [5]